Epstein Barr Virus Associated Lymphoma Consortium (EALC)
The Epstein Barr Virus Associated-Lymphoma Consortium (EALC) is advancing the understanding of the role of Epstein Barr virus (EBV) infection on Non-Hodgkin Lymphoma and/or Hodgkin disease development with or without an underlying HIV/AIDS infection.
The goal of the consortium is to increase knowledge about how EBV promotes Non-Hodgkin Lymphoma and/or Hodgkin disease initiation, progression, and resulting conditions, as well as to provide insights into mechanistic differences in the relationship between EBV infection and lymphoma development in individuals with HIV infection and those without an underlying HIV infection.
EALC Funding Opportunity
PAR-21-348: The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)
New grants for the EALC were awarded in Fall 2022.
Using single-cell sequencing and experimental models, Dr. Micah Luftig is characterizing and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas.
Drs. Sumita Bhaduri-McIntosh and Michael McIntosh are investigating synthetic lethal therapeutic strategies for EBV-positive diffuse large B-cell lymphoma (DLBCL) in people living with HIV infection.
Using preclinical models, Dr. Eric Johannsen is studying how an EBV protein interacts with the B cell receptor and maintains oncogenic antibody signaling in B cell lymphomas.
Drs. Ethel Cesarman, Benjamin Gewurz, and Lisa Roth are examining biological interactions between EBV and B cells involved in viral latency, and how these mechanisms play a role in the development of lymphoma in individuals living with HIV.
DCB Contact for EALC
For additional information about the EALC, please contact Dr. Betsy Read-Connole.